once standard therapies. Studies have shown that the prevalence of antibiotic resistance can vary widely by region and may be linked to outpatient consumption of antibiotics. 1, 2 The sheer number of bacteria exposed to oral antibiotics is so large that it is a statistical certainty that some bacteria will develop resistance to antibiotics. The greater the exposure of bacteria to a drug over years of clinical use, the more 'selection pressure' there is for resistance to emerge to that drug. While the operating assumption is that treatment-limiting resistance to all antibiotics will develop over time, this is true only if resistant bacteria survive to pass on resistance genes. 3 Most resistant ocular pathogens emerge as a result of widespread systemic antibiotic use, not specifically from ophthalmic antibiotic use. However, information on local, regional and global antibiotic resistance can be an important resource for ophthalmologists, especially when susceptibility data are available from ocular infections. Programmes that systematically monitor antibacterial susceptibility/resistance patterns provide critical information for the rational use of antibacterials. In vitro susceptibility testing of large numbers of isolates from multiple laboratories, compiled over time, can detect and track emerging resistance.
In susceptibility testing, minimum inhibitory concentrations (MICs) are interpreted as 'susceptible' or 'resistant' according to published standards. These interpretations are useful for predicting which drugs might be effective against a particular pathogen. Large-scale susceptibility surveillance has documented the potential durability of fluoroquinolone usefulness in the form of levofloxacin, which continues to exhibit in vitro activity against common ocular pathogens despite a decade of widespread oral and intravenous use for systemic illnesses. The durability of this antibacterial activity of levofloxacin has most recently been documented by nationwide surveillance programmes in the US. Staphylococcus aureus isolates for susceptibility testing, most of which (>80%) were methicillin-susceptible (MSSA). 4 The greatest in vitro activity against MSSA (>92% susceptibility) was seen with tobramycin and trimethoprim. Two antibacterials -polymyxin B and penicillin -were almost completely inactive against MSSA (<10% susceptibility), and azithromycin was only moderately active (54% susceptibility). The four fluoroquinolones tested -ciprofloxacin, gatifloxacin, levofloxacin and moxifloxacin -were indistinguishable in terms of MSSA susceptibility (80-81%).
Methicillin-resistant strains of S. aureus (MRSA) tested in Ocular TRUST 1 were multidrug-resistant pathogens with high-level resistance to fluoroquinolones, azithromycin and tobramycin (15, 6 and 36% susceptibility, respectively). MRSA isolates were fully resistant to penicillin and polymyxin B. The only antibiotic evaluated that retained high activity in MRSA was trimethoprim (94% susceptibility). Surveillance did not reveal any differences in susceptibility among the fluoroquinolones.
Ocular TRUST 1 -Streptococcus pneumoniae Susceptibility
Results from Ocular TRUST 1 showed that 100% of Streptococcus pneumoniae isolates were susceptible to levofloxacin, moxifloxacin and gatifloxacin; 5 10% of isolates showed intermediate susceptibility to ciprofloxacin. However, none of the 49 S. pneumoniae isolates was fully resistant to any of the fluoroquinolones. Non-susceptibility (intermediateplus-resistant S. pneumoniae isolates) to the other antibiotics tested ranged from 18% for penicillin to 22% for azithromycin and trimethoprim. Nonsusceptibility rates for tobramycin (98%) and polymyxin B (100%) indicated high-level S. pneumoniae resistance to these agents. S. pneumoniae isolates with intermediate or high-level resistance to penicillin (n=9) were susceptible only to levofloxacin, moxifloxacin and gatifloxacin.
Implications of Surveillance
The data from Ocular TRUST 1 correlate well with those from other largescale surveillance programmes. In archived ocular isolates collected over 
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MICs are often used to draw comparisons of potential antibacterial activity against specific pathogens. However, such comparisons assume that lower MICs translate into greater effectiveness clinically. However, using MICs as surrogate indicators of effectiveness overlooks critical factors that influence drug concentrations in target tissues and bacterial cells, and therefore also influence effectiveness. In addition, properties that affect the penetration and accumulation in ocular tissues must be considered. The solubility and lipophilicity of topical antibiotics will affect their tissue penetration and concentration, and will thus affect their bactericidal activity against encountered pathogens. 7
For an antibiotic to eradicate and prevent regrowth of pathogens, tissue concentrations must be maintained at bactericidal concentrations. 3 The achievable drug tissue concentration of topically applied ophthalmic antibiotics is influenced by the initial concentration of drug in tears. This can be especially critical to antibacterial activity since only a small percentage of instilled drug (perhaps less than 10%) may actually reach the site of an infection because of spillage, tear drainage and eye anatomy. 8 The aqueous solubility at physiological pH determines the drug concentrations that can be delivered with antibiotic application. Of the ophthalmic fluoroquinolones, ciprofloxacin is the least soluble, while levofloxacin is the most soluble at neutral or near-neutral pH. On the other hand, antibiotics must also be lipophilic in order to penetrate into tissue and sequestered bacteria. Fluorescence measurements of fluoroquinolone penetration in rabbit corneas found that both levofloxacin and gatifloxacin penetrated the epithelium significantly more than ciprofloxacin. 9 In keratoplasty patients, corneal tissue levels of ciprofloxacin and levofloxacin exceeded the MIC 90 of sight-threatening bacteria. 10 
